Tenpoint eyes presbyopia drug launch after FDA nod
Tenpoint is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, Orasis, and LENZ with a dual-acting rival.
Digital musculoskeletal care firm Sword buys rival Kaia
US digital physical therapy specialist Sword Health has bought its competitor Kaia Health for $285 million, positioning it for expansion in Europe.
Otsuka preps for July decision on centanafadine for ADHD
The FDA has started a priority review of Otsuka's triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.
Halozyme diversifies in drug delivery with Surf Bio buy
Halozyme has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio for up to $400m.
Eikon prices its IPO, seeking to raise $318m
Roger Perlmutter's new cancer biotech Eikon has priced its IPO, looking to raise up to $318m and achieve a $900m-plus valuation.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Book your tickets and join the PM Society for the 40th PM Aw...
Tickets are on sale for the 40th anniversary of the PM Awards
The Pharmaceutical Manufacturing and Packaging Congress (PHA...
The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 unites professionals to discuss the most recent trends of industry in Amsterdam
5th mRNA-Based Therapeutics Summit Europe
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines
VuuAI and Amiculum partner to transform content engagement i...
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat
10th Tumor Models Summit San Francisco
Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity